Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 17;13:945609. doi: 10.3389/fendo.2022.945609

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Xing, Zhao, Zhang and He

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Changes in gonadal parameters after MET and COM therapy. (A) Changes in E2 after MET and COM therapy. (B) Changes in LH after MET and COM therapy. (C) Changes in FSH after MET and COM therapy. (D) Changes in LH/FSH after MET and COM therapy. (E) Changes in PRL after MET and COM therapy. (F) Changes in Prog after MET and COM therapy. (G) Changes in TT after MET and COM therapy. (H) Changes in SHBG after MET and COM therapy. (I) Changes in FAI after MET and COM therapy. MET, metformin; COM, combine; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; PRL, prolactin; Prog, progesterone; TT, total testosterone; SHBG, sex hormone-binding globulin; FAI, free androgen index. Results are expressed as mean ± SD or median (25^th–75^th percentile); ^* P < 0.05, ^** P < 0.01 (vs. before treatment in each group); ^# P < 0.05, ^## P < 0.01 (vs. the other treatment).